Table IV.
Clinical Characteristics of Subjects with SAD by Ig Replacement Therapy
| Received Ig (N=10) | No Ig Received (N=46) | P-value | |
|---|---|---|---|
| Age, years (mean ± SD) | 53.10 ± 11.36 | 46.85 ± 11.22 | 0.12 |
| Female Sex | 7 (70.0%) | 31 (67.4%) | 0.60 |
| Caucasian | 4 (40.0%) | 36 (78.3%) | <0.05 |
| African American | 2 (20.0%) | 2 (4.3%) | <0.05 |
| Hispanic | 1 (10.0%) | 0 | <0.05 |
| Other/Unknown | 3 (30.0%) | 8 (17.4%) | <0.05 |
| # of pre-PPV titers >1.3μg/mL | 1.10 ± 1.37 | 1.62 ± 1.52 | 0.33 |
| # of post-PPV titers >1.3μg/mL | 2.70 ± 2.06 | 4.50 ± 1.57 | <0.05 |
| IgG, mg/dL (mean ± SD) | 860.10 ± 301.47 | 932.02 ± 257.32 | 0.44 |
| IgA, mg/dL (mean ± SD) | 117.80 ± 47.11 | 191.09 ± 85.95 | <0.05 |
| Allergic Rhinitis | 5 (50.0%) | 33 (71.7%) | 0.17 |
| Asthma | 9 (90.0%) | 31 (67.4%) | 0.15 |
| Imaging abnormalities | 6/8† (75.0%) | 17/29† (58.6%) | 0.34 |
| History of pneumonia | 4 (40.0%) | 5 (10.9%) | <0.05 |
| FESS | 5 (50.0%) | 25 (54.3%) | 0.54 |
| Antibiotics (mean ± SD) δ | 3.70 ± 2.31 | 3.07 ± 2.72 | 0.50 |
†
Denominators represent total number of individuals in each group that underwent an imaging modality (either chest CT or chest X-ray).
δ
Courses of antibiotics received in the two years following immunization.
PPV, polysaccharide pneumococcal vaccine; Ig, immunoglobulin; FESS, functional endoscopic sinus surgery